Rationale for tau aggregation inhibitor therapy in Alzheimer's disease and other tauopathies

Preprin

Tau-aggregation inhibitor therapy for Alzheimer's disease

Article Accepted Date: 9 December 2013 Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.Peer reviewedPublisher PD

Tau Aggregation Inhibitor Therapy : An Exploratory Phase 2 Study in Mild or Moderate Alzheimer's Disease

ACKNOWLEDGMENTS We thank patients and their caregivers for their participation in the study and are indebted to all the investigators involved in the study, particularly Drs. Douglas Fowlie and Donald Mowat for their helpful contributions to the clinical execution of the study in Scotland. We thank Sharon Eastwood, Parexel, for assistance in preparing initial drafts of the manuscript. We acknowledge constructive comments provided by Professors G. Wilcock and S. Gauthier on drafts of the article. CMW, CRH, and JMDS are officers of, and hold beneficial interests in, TauRx Therapeutics. RTS, PB, KK, and DJW are paid consultants to TauRx Therapeutics. The study was financed entirely by TauRx TherapeuticsPeer reviewedPublisher PD

Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer's Disease

Acknowledgments: Depolymerised bovine tubulin was kindly donated by J. Kilmartin (MRC Laboratory of Molecular Biology, Cambridge). This work was supported by the Medical Research Council (UK), a Wellcome Trust Studentship to RL, the Leopold Muller Estate, and the Newton Trust (Trinity College, Cambridge). We gratefully acknowledge Academic Books for permission to use Table 2 and Figures 2–4 which correspond to Table 1 and Figures 20–22 from Wischik C.M., Lai, R.Y.K. and Harrington, C.R. Modelling prion-like processing of tau protein in Alzheimer’s disease for pharmaceutical development, in Brain Microtubule Associated Proteins: Modifications in Disease, Avila, J.; Brandt, R.; Kosik, K.S., Eds. Harwood Academic Publishers: Amsterdam, The Netherlands, 1997. Erratum published on 12 August 2016, see Biomolecules 2016, 6(3), 35. http://www.mdpi.com/2218-273X/6/3/35Peer reviewedPublisher PD

A Meta-Analysis on Presynaptic Changes in Alzheimer's Disease

This work was funded by TauRx Therapeutics Ltd.,SingaporePeer reviewedPublisher PD

Hydromethylthionine enhancement of central cholinergic signalling is blocked by rivastigmine and memantine

The present study was carried out with funds supplied by TauRx Therapeutic Ltd. We are grateful to Helene Lau for assistance with 182 |KONDAK etAl.the analytical determinations. Open access funding enabled and or-ganized by ProjektDEAL TauRx Therapeutics Ltd., Aberdeen, Grant/Award Number: R0154Peer reviewedPublisher PD

Cortical Thickness and Surface Area Networks in Healthy Aging, Alzheimer’s Disease and Behavioral Variant Fronto-Temporal Dementia

Acknowledgments We would like to acknowledge the support of the Maxwell compute cluster funded by the University of Aberdeen. We also gratefully acknowledge study investigators and the generosity of study participants.Peer reviewedPublisher PD

Oral Tau Aggregation Inhibitor for Alzheimer’s Disease : Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate

Funding Information: We gratefully acknowledge the contribution of the scientific advisory board, study investigators, and the generosity of study participants. The authors thank EVERSANA™ for providing medical writing support, which was funded by TauRx Therapeutics in accordance with Good Publication Practice (GPP3) guidelines ( http://www.ismpp.org/gpp3 ). Publisher Copyright: © 2022, The Author(s).Peer reviewedPublisher PD

Proteomic analysis of hydromethylthionine in the line 66 model of frontotemporal dementia demonstrates actions on tau-dependent and tau-independent networks

Funding: This research received no external funding. Acknowledgments: The authors acknowledge Boris Neumann and Karola Lehmann for the excellent support with the proteomics data.Peer reviewedPublisher PD

Long-term hydromethylthionine treatment is associated with delayed clinical onset and slowing of cerebral atrophy in a pre-symptomatic P301S MAPT mutation carrier

ACKNOWLEDGMENTS We thank the patient for permitting publication of the present report. Authors’ disclosures available online (https://www.j-alz.com/manuscript-disclosures/21-0390r1).Peer reviewedPublisher PD